Daniel J. Lippis Sells 2,500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Edwards Lifesciences Stock Up 0.3 %

Shares of Edwards Lifesciences stock opened at $74.15 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market capitalization of $43.73 billion, a PE ratio of 10.70, a P/E/G ratio of 3.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50-day moving average of $69.72 and a 200-day moving average of $73.71.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 EPS. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Robert W. Baird lowered their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. UBS Group cut their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a research note on Monday. Stifel Nicolaus lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Finally, Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $79.40.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in EW. Wellington Management Group LLP increased its position in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after purchasing an additional 2,606,950 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares during the last quarter. Fisher Asset Management LLC raised its stake in Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after buying an additional 806,705 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $39,628,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.